Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Bioregulators · Dosing reference

Pancragen dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Not approved — research use onlyBLimited human dataNone established
Full research pageCycle-length evidenceComparePrefer Amiravo on Google
Regulatory status
Not approved — research use only
Human amounts
None established in humans
Route studied
Not stated in abstract
Frequency
Not established
Half-life
Not established
Evidence grade
Grade B · Limited human data
Vial sizes on the market
Not recorded
Other forms seen
—

What Pancragen is

Pancragen is a short synthetic peptide of the bioregulator class, studied in experimental research on pancreatic tissue and cellular aging.

The mechanism proposed by the peptide's developers is transcriptional: that KEDW acts on the transcription factors governing pancreatic cell differentiation. In cultures of human embryonic pancreatic cells aged by serial passage, pancragen was reported to increase expression of the acinar differentiation factors Pdx1 and Ptf1a and of the islet factors Pdx1, Pax6, Pax4, Foxa2 and Nkx2.2, with the authors naming those… How it works →

Key evidence

  • Korkushko et al., Bulletin of Experimental Biology and Medicine · 2011 · Humans (30 healthy older adults; 33 older patients with type 2 diabetes mellitus)
    In the diabetic group, pancragen was associated with lower fasting glucose, lower glucose on a standard glucose tolerance test, and lower plasma insulin and insulin resistance index; no change in carbohydrate metabolism indices was reported in patients not receiving it. Nocturnal melatonin was about 70% lower in diabetic than in healthy older participants. 2
  • Goncharova et al., Advances in Gerontology (in Russian) · 2015 · Animals (nine old, 20–25 year, clinically healthy female rhesus monkeys, Macaca mulatta)
    Both agents were associated with lower basal glucose; pancragen was additionally associated with normalisation of insulin and C-peptide levels, while glimepiride produced a more pronounced and delayed glucose-lowering effect with stimulated C-peptide secretion but little change in insulin. The authors' characterisation of the peptide as safe is not supported by any formal safety assessment in the report. 3
  • Goncharova et al., Advances in Gerontology (in Russian) · 2014 · Animals (old versus young female rhesus monkeys)
    Old animals showed a reduced glucose disappearance rate and higher insulin and C-peptide peaks than young animals; after pancragen the glucose disappearance rate increased and insulin and C-peptide dynamics were reported to normalise, with the effect partially retained three weeks after discontinuation. 4
All studies on the research page

What the human evidence shows

No approved or established human dose

We searched PubMed and ClinicalTrials.gov and found no human studies that administered Pancragen. The research described on its page is from cells or animals, and animal amounts do not translate to people.

How long did human studies run?

  • Pankragen forte was given for 4 weeks in the prediabetes study 15.
Cycle-length evidence for Pancragen

Who was excluded from the studies

  • The indexed studies enrolled older adults (with impaired glucose tolerance or type 2 diabetes); no study in younger adults receiving the peptide, children, pregnancy or lactation was identified 15,2.

Pancragen draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength
2 · Water added
3 · Amount per draw
4 · Syringe
Your mix
10 mg + 2 mL water = 5 mg/mL
10 units holds 0.5 mg (500 mcg)
Draw toEnter an amount in step 3
0102030405060708090100
U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Watermg/mLDraw
0.5 mL20—
1 mL10—
1.5 mL6.667—
2 mL5—
2.5 mL4—
3 mL3.333—
5 mL2—

Supplies and handling

  • Lyophilized vial
    Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
  • Sterile diluent
    The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
  • Graduated syringes
    Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
  • Alcohol prep pads
    For wiping vial stoppers before each puncture.
  • Nitrile gloves
    Clean gloves for aseptic handling.
  • Sharps container
    Puncture-resistant container for used needles.
Step-by-step reconstitution guideStorage and transport accessories

Storage

Handling should follow the certificate of analysis and written documentation supplied with the specific lot; no stability or handling data specific to this compound were identified in the sources reviewed. Short lyophilised peptides are generally treated as hygroscopic, light-sensitive solids whose reconstituted solutions are chemically less stable than the dry material. Amiravo does not provide preparation, reconstitution or administration instructions.

  • Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
  • Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
  • Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent
The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed
Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles
Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution
This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed
Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status
Not approved by the FDA for any use; no human drug labeling matching this name was returned by the openFDA Drug Label API 11.
United States (FDA)
There is no approved FDA application for this peptide; an openFDA Drug Label API query returned no matching human drug labeling 11. Neither "pancragen" nor "Lys-Glu-Asp-Trp" appears in any of the three categories of FDA's list of bulk drug substances nominated for use in compounding under section 503A of the FD&C Act, as updated 14 May 2026 12.
Sport (WADA)
Not named in the WADA 2026 Prohibited List 13. That absence is hedged negative evidence and not a clearance. Section S0 prohibits at all times "any pharmacological substance which is not currently approved by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use)" and states that the class "covers many different substances including but not limited to" its named examples; section S2 prohibits the listed peptide hormones, growth factors and mimetics "and other substances with similar chemical structure or similar biological effect(s)" 13.

Status varies by country and changes over time. How we describe regulatory status.

Pancragen compared with related compounds

CompoundStatusEvidenceHuman amountsHalf-life
PancragenNot approved — research use onlyBNone established—
VesugenNot approved — research use onlyCNone established—
BronchogenNot approved — research use onlyCNone established—
CardiogenNot approved — research use onlyCNone established—
CortagenNot approved — research use onlyCNone established—
PinealonNot approved — research use onlyCNone established—

Frequently asked questions

What doses of Pancragen have been studied in humans?
None that establish an amount. Pancragen is not approved anywhere and we found no human studies that administered it. Amiravo does not publish community or vendor figures.
Is there an established Pancragen cycle length?
No cycle length or break has been established. Human studies administered Pancragen for the periods listed on this page; those are study durations, not a recommended course.
How much bacteriostatic water should be added to a Pancragen vial?
There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.
How many units is a given amount on an insulin syringe?
On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.
Is Pancragen FDA-approved?
Not approved — research use only. Not approved by the FDA for any use; no human drug labeling matching this name was returned by the openFDA Drug Label API 11.

References

  1. lysyl-glutamyl-aspartyl-tryptophanamide [Supplementary Concept] — entry terms Lys-Glu-Asp-Trp-NH2, KEDW-NH2, pancragen Medical Subject Headings, U.S. National Library of Medicine. 2026
  2. Prospects of using pancragen for correction of metabolic disorders in elderly people Bulletin of Experimental Biology and Medicine. 2011
  3. Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys (in Russian) Advances in Gerontology (Uspekhi Gerontologii). 2015
  4. Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys (in Russian) Advances in Gerontology (Uspekhi Gerontologii). 2014
  5. Effects of pancragen on the differentiation of pancreatic cells during their ageing Bulletin of Experimental Biology and Medicine. 2013
  6. Peptides tissue-specifically stimulate cell differentiation during their aging Bulletin of Experimental Biology and Medicine. 2012
  7. Tetrapeptide stimulates functional activity of the pancreatic cells in aging (in Russian) Advances in Gerontology (Uspekhi Gerontologii). 2012
  8. Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide Bulletin of Experimental Biology and Medicine. 2010
  9. Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus Bulletin of Experimental Biology and Medicine. 2007
  10. ClinicalTrials.gov registry query for "pancragen" (0 studies returned) ClinicalTrials.gov (U.S. National Library of Medicine). 2026
  11. openFDA Drug Label API query for "pancragen" (no approved human drug labeling for a peptide of this name) U.S. Food and Drug Administration / openFDA. 2026
  12. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) U.S. Food and Drug Administration. 2026
  13. World Anti-Doping Code International Standard — Prohibited List 2026 (effective 1 January 2026) World Anti-Doping Agency. 2026
  14. PubMed query for "pancragen" (9 records) PubMed / NCBI Entrez (U.S. National Library of Medicine). 2026
  15. [The tetrapeptide pankragen forte efficiency in elderly people with prediabetic state] Adv Gerontol. 2013

Last reviewed October 23, 2026 by the Amiravo editorial team. Editorial policy · Report an error